EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

G. Roberts, O. Pfaar, C. A. Akdis, I. J. Ansotegui, S. R. Durham, R. Gerth van Wijk, S. Halken, D. Larenas-Linnemann, R. Pawankar, C. Pitsios, A. Sheikh, M. Worm, S. Arasi, M. A. Calderon, C. Cingi, S. Dhami, J. L. Fauquert, E. Hamelmann, P. Hellings, L. JacobsenE. F. Knol, S. Y. Lin, P. Maggina, R. Mösges, J. N.G. Oude Elberink, G. B. Pajno, E. A. Pastorello, M. Penagos, G. Rotiroti, C. B. Schmidt-Weber, F. Timmermans, O. Tsilochristou, E. M. Varga, J. N. Wilkinson, A. Williams, L. Zhang, I. Agache, E. Angier, M. Fernandez-Rivas, M. Jutel, S. Lau, R. van Ree, D. Ryan, G. J. Sturm, A. Muraro

Research output: Contribution to journalArticle

Abstract

Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project “EAACI Guidelines on Allergen Immunotherapy.” It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children.

Original languageEnglish (US)
Pages (from-to)765-798
Number of pages34
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume73
Issue number4
DOIs
StatePublished - Apr 2018

Fingerprint

Immunologic Desensitization
Allergy and Immunology
Guidelines
Poaceae
Drug Therapy
Nose
Allergens
Tablets
Meta-Analysis
Quality of Life
Therapeutics
Population

Keywords

  • allergen immunotherapy
  • allergic conjunctivitis
  • allergic rhinitis
  • allergy
  • rhinoconjunctivitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Roberts, G., Pfaar, O., Akdis, C. A., Ansotegui, I. J., Durham, S. R., Gerth van Wijk, R., ... Muraro, A. (2018). EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 73(4), 765-798. https://doi.org/10.1111/all.13317

EAACI Guidelines on Allergen Immunotherapy : Allergic rhinoconjunctivitis. / Roberts, G.; Pfaar, O.; Akdis, C. A.; Ansotegui, I. J.; Durham, S. R.; Gerth van Wijk, R.; Halken, S.; Larenas-Linnemann, D.; Pawankar, R.; Pitsios, C.; Sheikh, A.; Worm, M.; Arasi, S.; Calderon, M. A.; Cingi, C.; Dhami, S.; Fauquert, J. L.; Hamelmann, E.; Hellings, P.; Jacobsen, L.; Knol, E. F.; Lin, S. Y.; Maggina, P.; Mösges, R.; Oude Elberink, J. N.G.; Pajno, G. B.; Pastorello, E. A.; Penagos, M.; Rotiroti, G.; Schmidt-Weber, C. B.; Timmermans, F.; Tsilochristou, O.; Varga, E. M.; Wilkinson, J. N.; Williams, A.; Zhang, L.; Agache, I.; Angier, E.; Fernandez-Rivas, M.; Jutel, M.; Lau, S.; van Ree, R.; Ryan, D.; Sturm, G. J.; Muraro, A.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 4, 04.2018, p. 765-798.

Research output: Contribution to journalArticle

Roberts, G, Pfaar, O, Akdis, CA, Ansotegui, IJ, Durham, SR, Gerth van Wijk, R, Halken, S, Larenas-Linnemann, D, Pawankar, R, Pitsios, C, Sheikh, A, Worm, M, Arasi, S, Calderon, MA, Cingi, C, Dhami, S, Fauquert, JL, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, EF, Lin, SY, Maggina, P, Mösges, R, Oude Elberink, JNG, Pajno, GB, Pastorello, EA, Penagos, M, Rotiroti, G, Schmidt-Weber, CB, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, JN, Williams, A, Zhang, L, Agache, I, Angier, E, Fernandez-Rivas, M, Jutel, M, Lau, S, van Ree, R, Ryan, D, Sturm, GJ & Muraro, A 2018, 'EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis', Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 4, pp. 765-798. https://doi.org/10.1111/all.13317
Roberts, G. ; Pfaar, O. ; Akdis, C. A. ; Ansotegui, I. J. ; Durham, S. R. ; Gerth van Wijk, R. ; Halken, S. ; Larenas-Linnemann, D. ; Pawankar, R. ; Pitsios, C. ; Sheikh, A. ; Worm, M. ; Arasi, S. ; Calderon, M. A. ; Cingi, C. ; Dhami, S. ; Fauquert, J. L. ; Hamelmann, E. ; Hellings, P. ; Jacobsen, L. ; Knol, E. F. ; Lin, S. Y. ; Maggina, P. ; Mösges, R. ; Oude Elberink, J. N.G. ; Pajno, G. B. ; Pastorello, E. A. ; Penagos, M. ; Rotiroti, G. ; Schmidt-Weber, C. B. ; Timmermans, F. ; Tsilochristou, O. ; Varga, E. M. ; Wilkinson, J. N. ; Williams, A. ; Zhang, L. ; Agache, I. ; Angier, E. ; Fernandez-Rivas, M. ; Jutel, M. ; Lau, S. ; van Ree, R. ; Ryan, D. ; Sturm, G. J. ; Muraro, A. / EAACI Guidelines on Allergen Immunotherapy : Allergic rhinoconjunctivitis. In: Allergy: European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 4. pp. 765-798.
@article{49c62039e53849fbbfec78a7fb57a7e2,
title = "EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis",
abstract = "Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project “EAACI Guidelines on Allergen Immunotherapy.” It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children.",
keywords = "allergen immunotherapy, allergic conjunctivitis, allergic rhinitis, allergy, rhinoconjunctivitis",
author = "G. Roberts and O. Pfaar and Akdis, {C. A.} and Ansotegui, {I. J.} and Durham, {S. R.} and {Gerth van Wijk}, R. and S. Halken and D. Larenas-Linnemann and R. Pawankar and C. Pitsios and A. Sheikh and M. Worm and S. Arasi and Calderon, {M. A.} and C. Cingi and S. Dhami and Fauquert, {J. L.} and E. Hamelmann and P. Hellings and L. Jacobsen and Knol, {E. F.} and Lin, {S. Y.} and P. Maggina and R. M{\"o}sges and {Oude Elberink}, {J. N.G.} and Pajno, {G. B.} and Pastorello, {E. A.} and M. Penagos and G. Rotiroti and Schmidt-Weber, {C. B.} and F. Timmermans and O. Tsilochristou and Varga, {E. M.} and Wilkinson, {J. N.} and A. Williams and L. Zhang and I. Agache and E. Angier and M. Fernandez-Rivas and M. Jutel and S. Lau and {van Ree}, R. and D. Ryan and Sturm, {G. J.} and A. Muraro",
year = "2018",
month = "4",
doi = "10.1111/all.13317",
language = "English (US)",
volume = "73",
pages = "765--798",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - EAACI Guidelines on Allergen Immunotherapy

T2 - Allergic rhinoconjunctivitis

AU - Roberts, G.

AU - Pfaar, O.

AU - Akdis, C. A.

AU - Ansotegui, I. J.

AU - Durham, S. R.

AU - Gerth van Wijk, R.

AU - Halken, S.

AU - Larenas-Linnemann, D.

AU - Pawankar, R.

AU - Pitsios, C.

AU - Sheikh, A.

AU - Worm, M.

AU - Arasi, S.

AU - Calderon, M. A.

AU - Cingi, C.

AU - Dhami, S.

AU - Fauquert, J. L.

AU - Hamelmann, E.

AU - Hellings, P.

AU - Jacobsen, L.

AU - Knol, E. F.

AU - Lin, S. Y.

AU - Maggina, P.

AU - Mösges, R.

AU - Oude Elberink, J. N.G.

AU - Pajno, G. B.

AU - Pastorello, E. A.

AU - Penagos, M.

AU - Rotiroti, G.

AU - Schmidt-Weber, C. B.

AU - Timmermans, F.

AU - Tsilochristou, O.

AU - Varga, E. M.

AU - Wilkinson, J. N.

AU - Williams, A.

AU - Zhang, L.

AU - Agache, I.

AU - Angier, E.

AU - Fernandez-Rivas, M.

AU - Jutel, M.

AU - Lau, S.

AU - van Ree, R.

AU - Ryan, D.

AU - Sturm, G. J.

AU - Muraro, A.

PY - 2018/4

Y1 - 2018/4

N2 - Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project “EAACI Guidelines on Allergen Immunotherapy.” It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children.

AB - Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project “EAACI Guidelines on Allergen Immunotherapy.” It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children.

KW - allergen immunotherapy

KW - allergic conjunctivitis

KW - allergic rhinitis

KW - allergy

KW - rhinoconjunctivitis

UR - http://www.scopus.com/inward/record.url?scp=85032825167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032825167&partnerID=8YFLogxK

U2 - 10.1111/all.13317

DO - 10.1111/all.13317

M3 - Article

C2 - 28940458

AN - SCOPUS:85032825167

VL - 73

SP - 765

EP - 798

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 4

ER -